A subsidiary of Fujifilm Corp., Fujifilm Diosynth Biotechnologies has become an industry leader in biologics and advanced therapies as it brings new value to society by re-innovating its business.
In 2019, Fujifilm Diosynth Biotechnologies acquired the Hillerod Manufacturing site, a large-scale biologics manufacturing site from Biogen Denmark Manufacturing ApS, making it the company’s fourth biopharmaceutical manufacturing site and positioning itself as one of the main Biologics Contract Development and Manufacturing Organizations.
“Health care is the fastest growing sector we have, and this acquisition is just the beginning of our focus on biologics versus traditional chemical logs,” said Lars Petersen, Chief Operating Officer of Fujifilm Diosynth Bio technologies, Hillerod, Denmark.
Through the acquisition of the Biogen manufacturing site, Fujifilm Diosynth Biotechnologies has been given a chance to carry on with its objective of creating new technologies, products, and services.
“We hope to maximize our skill in innovating and learning (about) the life science industry, as well as adapting to the culture of the staff and leadership in the company, which came with the acquisition. This acquisition gave us the opportunity to expand the business and closely monitor production for innovative companies in the sector,” Petersen said.
“It will also enable us to ensure the quality of our products, from manufacturing and packaging all the way to the final client with a fully integrated business. This goes in line with the company’s values where the patient is always the center of our focus.”
As the company approaches new milestones, it aims to double the size of its operations, as well as create a more sustainable business for its clients.
“We believe this objective is achievable due to the positive results from our acquisition. With a business like ours in Denmark, we hope to strengthen the connection we have with our customers,” Petersen said.
